Standard BioTools Future Growth
Future criteria checks 1/6
Standard BioTools is forecast to grow earnings and revenue by 8.1% and 16.4% per annum respectively while EPS is expected to grow by 4.8% per annum.
Key information
8.1%
Earnings growth rate
4.8%
EPS growth rate
| Life Sciences earnings growth | 17.8% |
| Revenue growth rate | 16.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Jan 2024 |
Recent future growth updates
Recent updates
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S
Dec 19
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target
Nov 10SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable
Apr 17Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term
Apr 02SomaLogic appoints former Foundation Medicine chief as executive chair
Oct 17SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay
Jul 26We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely
Jun 06SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside
Apr 12Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)
Mar 09We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth
Dec 28SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics
Oct 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 140 | -69 | N/A | -81 | 2 |
| 12/31/2025 | 118 | -84 | N/A | -87 | 2 |
| 12/31/2024 | 99 | -100 | N/A | -91 | 4 |
| 12/31/2023 | 84 | -111 | N/A | -113 | 4 |
| 9/30/2023 | 82 | -130 | -122 | -117 | N/A |
| 6/30/2023 | 101 | -141 | -139 | -134 | N/A |
| 3/31/2023 | 95 | -139 | -144 | -138 | N/A |
| 12/31/2022 | 98 | -109 | -106 | -101 | N/A |
| 9/30/2022 | 102 | -83 | -96 | -92 | N/A |
| 6/30/2022 | 80 | -92 | -75 | -70 | N/A |
| 3/31/2022 | 86 | -82 | -46 | -42 | N/A |
| 12/31/2021 | 82 | -88 | -44 | -40 | N/A |
| 9/30/2021 | 87 | -73 | -27 | -23 | N/A |
| 6/30/2021 | 81 | -39 | -13 | -11 | N/A |
| 3/31/2021 | 68 | -45 | -22 | -21 | N/A |
| 12/31/2020 | 56 | -53 | -29 | -28 | N/A |
| 12/31/2019 | 32 | -57 | -51 | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLGC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLGC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLGC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLGC's revenue (16.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: SLGC's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLGC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/09 16:35 |
| End of Day Share Price | 2024/01/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Brandon Couillard | Jefferies LLC |
| Daniel Brennan | TD Cowen |